semaglutide china China's weight-loss drug makers take on global giants as Novo Nordisk patent expires China approves Wegovy weight-loss drug

Food loses its grip on your mind

Why Combining These Treatments Works Using GLP-1 agonists alone can lead to great weight loss, but some patients experience challenges such as muscle loss, disproportionate fat loss, or loose skin

Upcoming weight loss treatments High-strength oral semaglutide Orforglipron: Once-daily pill (expected in 2026) CagriSema: Combined treatment (expected mid-2027) Retatrutide: Triple-action treatment (expected 2027) MariTide: Long-lasting GLP-1 and GIP treatment (expected 2028-29) Survodutide: Glucagon+GLP-1 receptor dual agonist (expected late 2020s) Amycretin: GLP-1 combined with amylin (expected 2030) References Since semaglutide was approved for use in September 2023, the landscape for weight loss treatments in the UK was dramatically transformed, with thousands of people achieving significant results from GLP-1 treatments

This bioavailability gap has direct implications for dosing